Therapy with cultured T cells: principles revisited

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• T-cell therapy demonstrates efficacy in treating advanced disseminated leukemia in both animals and humans.
• The therapeutic impact of T-cell therapy is dose-dependent, with increased effector T cells correlating with improved survival rates.
• Procuring substantial numbers of immune effector T cells is crucial for effective T-cell therapy.

Purpose of the Study:

• To explore the potential of cultured T cells for expanding immune effector T cells in vivo beyond vaccination levels.
• To investigate the factors influencing the survival and function of cultured T cells in vivo, including culture conditions and therapeutic regimens.
• To validate the use of peptide immunization and T-cell clones for eradicating leukemia and discuss future target selection for T-cell therapy.

Main Methods:

• Expanding immune T cells in vitro to achieve large quantities for in vivo administration.
• Utilizing peptide immunization to circumvent the need for whole-tumor immunization, leveraging T cells' recognition of peptides.
• Employing cloned T cells and established culture conditions to direct T-cell therapy against specific antigens.

Main Results:

• Cultured T cells can be expanded in vivo to levels unattainable by vaccination, leading to increased survival.
• Appropriate culture conditions and therapeutic regimens ensure the proliferation, wide distribution, and long-term survival of cultured T cells in vivo.
• Peptide-specific T cells and cloned T cells have demonstrated efficacy in eradicating leukemia in murine models and have been validated in human clinical trials.

Conclusions:

• T-cell therapy, particularly using cultured and cloned T cells, offers a viable and potent strategy for treating advanced leukemia.
• Peptide-based immunization combined with optimized T-cell culture techniques allows for targeted T-cell therapy against a broad range of host antigens.
• Identifying optimal protein and peptide targets remains a critical area for advancing T-cell therapy trials.